ScholarIQanswers from OpenAlex & ORCID
Fortunato Ciardiello
ResearcherPublications, citations & collaboration network
Fortunato Ciardiello is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fortunato Ciardiello have?
ScholarIQindexed works
Fortunato Ciardiello has 1,032 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fortunato Ciardiello have?
ScholarIQcitation count
Fortunato Ciardiello has 64,966 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fortunato Ciardiello?
ScholarIQh-index
Fortunato Ciardiello has an h-index of 107 in OpenAlex.
What is the i10-index of Fortunato Ciardiello?
ScholarIQi10-index
Fortunato Ciardiello has an i10-index of 515 in OpenAlex.
What is the ORCID of Fortunato Ciardiello?
ScholarIQorcid
The ORCID for Fortunato Ciardiello is on the source record.
What is the OpenAlex record for Fortunato Ciardiello?
ScholarIQopenalex
The OpenAlex for Fortunato Ciardiello is on the source record.
What are the most-cited papers on Fortunato Ciardiello?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T. Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent‐Puig, Frédérique Penault–Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric FIORE, Alice Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M. Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
Alexander R. Lyon, Susan Dent, Susannah Stanway, Helena Earl, Christine Brezden‐Masley, Alain Cohen‐Solal, Carlo G. Tocchetti, Javid J. Moslehi, John D. Groarke, Jutta Bergler‐Klein, Vincent Khoo, Li Ling Tan, Markus S. Anker, Stephan von Haehling, Christoph Maack, Radek Pudil, Ana Barac, Paaladinesh Thavendiranathan, Bonnie Ky, Tomas G. Neilan, Yu. N. Belenkov, Stuart D. Rosen, Zaza Iakobishvili, Aaron L. Sverdlov, Ludhmila Abrahão Hajjar, Ariane Vieira Scarlatelli Macedo, Charlotte Manisty, Fortunato Ciardiello, Dimitrios Farmakis, Rudolf A. de Boer, Hadi Skouri, Thomas Suter, Daniela Cardinale, Ronald Witteles, Michael G. Fradley, Joerg Herrmann, Robert F. Cornell, Ashutosh Wechelaker, Michael J. Mauro, Dragana Milojković, Hugues de Lavallade, Frank Ruschitzka, Andrew J.S. Coats, Petar Seferović, Ovidiu Chioncel, Thomas Thum, Johann Bauersachs, María Sol Andrés, David J. Wright, Teresa López‐Fernández, Chris Plummer, Daniel J. Lenihan